Navigation Links
Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
Date:9/12/2007

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, September 12 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today the company's Chief Scientist Prof. Zvi Bentwich will present AACR's upcoming Molecular Diagnostics in Cancer Therapeutic Development conference. Prof. Bentwich's presentation will focus on Rosetta Genomics unique microRNA-based technologies and current development programs. The event will take place at the Atlanta Hilton, Atlanta.

The presentation, titled, "Human microRNAs: Powerful Biomarkers for Cancer Diagnostics", is part of a plenary session on the molecular classification of tumors, which will be held on Wednesday, September 19, between 10:45 am-1:00 pm.

An audio webcast of the presentation will be made available by AACR 15 days after the conference at the following url: http://www.aacr.org/home/scientists/meetings--workshops/molecular-diagnosti c s-in-cancer-therapeutic-development.aspx

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

About Rosetta Genomics

Rosetta Genomics (Nasdaq:ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and various diseases. For more information please visit: http://www.rosettagenomics.com

Contact:

Media

Alan Zachary

T: +1-312-944-6784

media@rosettagenomics.com

Investors

Juliane Snowden

T: +1-212-213-0006

investors@rosettagenomics.com


'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
2. Genomics researcher Hood joins NimbleGen board
3. GE Healthcare partners with genomics institute
4. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
5. Wisconsin firms to present at Cleantech venture capital event
6. New Sonic Foundry search engine finds words, phrases in video presentations
7. Lone Wisconsin firm to present at InvestMidwest
8. Sonic Foundry creates search engine for 7,000 expert video presentations
9. InvestMidWest calls for business presentations
10. Wicab to present BrainPort at Boston conference
11. Three more Wisconsin firms to present at venture forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):